MovDisordV3, Main, Exploration, bibRecord, 001B85

Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications

Identifieur interne : 001B85 ( Main/Exploration ); précédent : 001B84; suivant : 001B86

Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications

Auteurs : Markus Naumann [Allemagne] ; Alastair Carruthers [Canada] ; Jean Carruthers [Canada] ; Sheena K. Aurora [États-Unis] ; Ross Zafonte [États-Unis] ; Susan Abu-Shakra [États-Unis] ; Terry Boodhoo [États-Unis] ; Mary Ann Miller-Messana [États-Unis] ; George Demos [États-Unis] ; Lynn James [États-Unis] ; Frederick Beddingfield [États-Unis] ; Amanda Vandenburgh [États-Unis] ; Mary Ann Chapman [États-Unis] ; Mitchell F. Brin [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2010-10-15.

RBID : ISTEX:9D49D0608959680754775765CD828182E3869E3E

Descripteurs français

Pascal (Inist)
- Bontoxilysin, Changement médicament, Dystonie, Esthétique, Hyperhidrose, Hypertonie spastique, Immunogénicité, Indication, Pathologie du système nerveux, Vessie hyperactive.

English descriptors

KwdEn :
- Adult, Aesthetics, Antibodies, Neutralizing (blood), Bontoxilysin, Botulinum Toxins, Type A (immunology), Botulinum Toxins, Type A (therapeutic use), Drug conversion, Dystonia, Follow-Up Studies, Humans, Hyperhidrosis, Immunogenicity, Indication, Middle Aged, Movement Disorders (blood), Movement Disorders (drug therapy), Movement Disorders (immunology), Nervous system diseases, Overactive bladder, Prospective Studies, Spasticity, antigenicity, botulinum toxin, cervical dystonia, facial aesthetics, hyperhidrosis, immunogenicity, neutralizing antibodies, overactive bladder, spasticity.
MESH :
- chemical , blood : Antibodies, Neutralizing.
- chemical , immunology : Botulinum Toxins, Type A.
- chemical , therapeutic use : Botulinum Toxins, Type A.
- blood : Movement Disorders.
- drug therapy : Movement Disorders.
- immunology : Movement Disorders.
- Adult, Follow-Up Studies, Humans, Middle Aged, Prospective Studies.

Abstract

This meta‐analysis evaluated the frequency of neutralizing antibody (nAb) conversion with onabotulinumtoxinA (BOTOX®; Allergan) across five studied indications. The analysis was based on large, controlled or prospective, open‐label trials (durations 4 months to ≥2 years). Serum samples were analyzed for nAbs using the Mouse Protection Assay. Subjects who were antibody negative at baseline and had at least one analyzable postbaseline antibody assay result were included. The 16 clinical studies included 3,006 subjects; of these, 2,240 met the inclusion criteria for this analysis. Subjects received 1–15 treatments (mean 3.8 treatments) with onabotulinumtoxinA. Total doses per treatment cycle ranged from 10 or 20 units in glabellar lines to 20–500 units in cervical dystonia. The numbers of subjects who converted from an antibody‐negative status at baseline to antibody‐positive status at any post‐treatment time point were: cervical dystonia 4/312 (1.28%), glabellar lines 2/718 (0.28%), overactive bladder 0/22 (0%), post‐stroke spasticity 1/317 (0.32%), and primary axillary hyperhidrosis 4/871 (0.46%). Across all indications, 11/2,240 subjects (0.49%) converted from antibody negative at baseline to positive at one or more post‐treatment time points, but only three subjects became clinically unresponsive to onabotulinumtoxinA at some point following a positive assay. Based on these large trials, the frequency of antibody conversion after onabotulinumtoxinA treatment is very low, and infrequently leads to loss of efficacy. © 2010 Movement Disorder Society

Url:

https://api.istex.fr/document/9D49D0608959680754775765CD828182E3869E3E/fulltext/pdf

DOI: 10.1002/mds.23254

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications</title>
<author><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name>
</author>
<author><name sortKey="Carruthers, Alastair" sort="Carruthers, Alastair" uniqKey="Carruthers A" first="Alastair" last="Carruthers">Alastair Carruthers</name>
</author>
<author><name sortKey="Carruthers, Jean" sort="Carruthers, Jean" uniqKey="Carruthers J" first="Jean" last="Carruthers">Jean Carruthers</name>
</author>
<author><name sortKey="Aurora, Sheena K" sort="Aurora, Sheena K" uniqKey="Aurora S" first="Sheena K." last="Aurora">Sheena K. Aurora</name>
</author>
<author><name sortKey="Zafonte, Ross" sort="Zafonte, Ross" uniqKey="Zafonte R" first="Ross" last="Zafonte">Ross Zafonte</name>
</author>
<author><name sortKey="Abu Hakra, Susan" sort="Abu Hakra, Susan" uniqKey="Abu Hakra S" first="Susan" last="Abu-Shakra">Susan Abu-Shakra</name>
</author>
<author><name sortKey="Boodhoo, Terry" sort="Boodhoo, Terry" uniqKey="Boodhoo T" first="Terry" last="Boodhoo">Terry Boodhoo</name>
</author>
<author><name sortKey="Miller Essana, Mary Ann" sort="Miller Essana, Mary Ann" uniqKey="Miller Essana M" first="Mary Ann" last="Miller-Messana">Mary Ann Miller-Messana</name>
</author>
<author><name sortKey="Demos, George" sort="Demos, George" uniqKey="Demos G" first="George" last="Demos">George Demos</name>
</author>
<author><name sortKey="James, Lynn" sort="James, Lynn" uniqKey="James L" first="Lynn" last="James">Lynn James</name>
</author>
<author><name sortKey="Beddingfield, Frederick" sort="Beddingfield, Frederick" uniqKey="Beddingfield F" first="Frederick" last="Beddingfield">Frederick Beddingfield</name>
</author>
<author><name sortKey="Vandenburgh, Amanda" sort="Vandenburgh, Amanda" uniqKey="Vandenburgh A" first="Amanda" last="Vandenburgh">Amanda Vandenburgh</name>
</author>
<author><name sortKey="Chapman, Mary Ann" sort="Chapman, Mary Ann" uniqKey="Chapman M" first="Mary Ann" last="Chapman">Mary Ann Chapman</name>
</author>
<author><name sortKey="Brin, Mitchell F" sort="Brin, Mitchell F" uniqKey="Brin M" first="Mitchell F." last="Brin">Mitchell F. Brin</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:9D49D0608959680754775765CD828182E3869E3E</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.23254</idno>
<idno type="url">https://api.istex.fr/document/9D49D0608959680754775765CD828182E3869E3E/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000485</idno>
<idno type="wicri:Area/Istex/Curation">000485</idno>
<idno type="wicri:Area/Istex/Checkpoint">000864</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Naumann M:meta:analysis:of</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:20737546</idno>
<idno type="wicri:Area/PubMed/Corpus">001609</idno>
<idno type="wicri:Area/PubMed/Curation">001609</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001782</idno>
<idno type="wicri:Area/Ncbi/Merge">002E08</idno>
<idno type="wicri:Area/Ncbi/Curation">002E08</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002E08</idno>
<idno type="wicri:Area/Main/Merge">002021</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:10-0474351</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000877</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002442</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000968</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Naumann M:meta:analysis:of</idno>
<idno type="wicri:Area/Main/Merge">002555</idno>
<idno type="wicri:Area/Main/Curation">001B85</idno>
<idno type="wicri:Area/Main/Exploration">001B85</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications</title>
<author><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Augsburg Neurologische Klinik, Augsburg</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Souabe</region>
<settlement type="city">Augsbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Carruthers, Alastair" sort="Carruthers, Alastair" uniqKey="Carruthers A" first="Alastair" last="Carruthers">Alastair Carruthers</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Dermatology and Skin Science, University of British Columbia</wicri:regionArea>
<wicri:noRegion>University of British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Carruthers, Jean" sort="Carruthers, Jean" uniqKey="Carruthers J" first="Jean" last="Carruthers">Jean Carruthers</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Ophthalmology and Visual Sciences, University of British Columbia</wicri:regionArea>
<wicri:noRegion>University of British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Aurora, Sheena K" sort="Aurora, Sheena K" uniqKey="Aurora S" first="Sheena K." last="Aurora">Sheena K. Aurora</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Swedish Pain and Headache Center, Seattle, Washington</wicri:regionArea>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zafonte, Ross" sort="Zafonte, Ross" uniqKey="Zafonte R" first="Ross" last="Zafonte">Ross Zafonte</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Harvard Medical School, Spaulding Rehabilitation Hospital Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Abu Hakra, Susan" sort="Abu Hakra, Susan" uniqKey="Abu Hakra S" first="Susan" last="Abu-Shakra">Susan Abu-Shakra</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Allergan, Inc., Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Current Address: Elan Pharmaceuticals, Inc., South San Francisco</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Boodhoo, Terry" sort="Boodhoo, Terry" uniqKey="Boodhoo T" first="Terry" last="Boodhoo">Terry Boodhoo</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Allergan, Inc., Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Miller Essana, Mary Ann" sort="Miller Essana, Mary Ann" uniqKey="Miller Essana M" first="Mary Ann" last="Miller-Messana">Mary Ann Miller-Messana</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Allergan, Inc., Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Demos, George" sort="Demos, George" uniqKey="Demos G" first="George" last="Demos">George Demos</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Allergan, Inc., Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="James, Lynn" sort="James, Lynn" uniqKey="James L" first="Lynn" last="James">Lynn James</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Allergan, Inc., Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Beddingfield, Frederick" sort="Beddingfield, Frederick" uniqKey="Beddingfield F" first="Frederick" last="Beddingfield">Frederick Beddingfield</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Allergan, Inc., Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles</wicri:regionArea>
<placeName><settlement type="city">Los Angeles</settlement>
<region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vandenburgh, Amanda" sort="Vandenburgh, Amanda" uniqKey="Vandenburgh A" first="Amanda" last="Vandenburgh">Amanda Vandenburgh</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Allergan, Inc., Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chapman, Mary Ann" sort="Chapman, Mary Ann" uniqKey="Chapman M" first="Mary Ann" last="Chapman">Mary Ann Chapman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Visage Communications, Mead, Washington</wicri:regionArea>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brin, Mitchell F" sort="Brin, Mitchell F" uniqKey="Brin M" first="Mitchell F." last="Brin">Mitchell F. Brin</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Allergan, Inc., Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of California, Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-10-15">2010-10-15</date>
<biblScope unit="vol">25</biblScope>
<biblScope unit="issue">13</biblScope>
<biblScope unit="page" from="2211">2211</biblScope>
<biblScope unit="page" to="2218">2218</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">9D49D0608959680754775765CD828182E3869E3E</idno>
<idno type="DOI">10.1002/mds.23254</idno>
<idno type="ArticleID">MDS23254</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aesthetics</term>
<term>Antibodies, Neutralizing (blood)</term>
<term>Bontoxilysin</term>
<term>Botulinum Toxins, Type A (immunology)</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Drug conversion</term>
<term>Dystonia</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Hyperhidrosis</term>
<term>Immunogenicity</term>
<term>Indication</term>
<term>Middle Aged</term>
<term>Movement Disorders (blood)</term>
<term>Movement Disorders (drug therapy)</term>
<term>Movement Disorders (immunology)</term>
<term>Nervous system diseases</term>
<term>Overactive bladder</term>
<term>Prospective Studies</term>
<term>Spasticity</term>
<term>antigenicity</term>
<term>botulinum toxin</term>
<term>cervical dystonia</term>
<term>facial aesthetics</term>
<term>hyperhidrosis</term>
<term>immunogenicity</term>
<term>neutralizing antibodies</term>
<term>overactive bladder</term>
<term>spasticity</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Botulinum Toxins, Type A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Prospective Studies</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Bontoxilysin</term>
<term>Changement médicament</term>
<term>Dystonie</term>
<term>Esthétique</term>
<term>Hyperhidrose</term>
<term>Hypertonie spastique</term>
<term>Immunogénicité</term>
<term>Indication</term>
<term>Pathologie du   système nerveux</term>
<term>Vessie hyperactive</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This meta‐analysis evaluated the frequency of neutralizing antibody (nAb) conversion with onabotulinumtoxinA (BOTOX®; Allergan) across five studied indications. The analysis was based on large, controlled or prospective, open‐label trials (durations 4 months to ≥2 years). Serum samples were analyzed for nAbs using the Mouse Protection Assay. Subjects who were antibody negative at baseline and had at least one analyzable postbaseline antibody assay result were included. The 16 clinical studies included 3,006 subjects; of these, 2,240 met the inclusion criteria for this analysis. Subjects received 1–15 treatments (mean 3.8 treatments) with onabotulinumtoxinA. Total doses per treatment cycle ranged from 10 or 20 units in glabellar lines to 20–500 units in cervical dystonia. The numbers of subjects who converted from an antibody‐negative status at baseline to antibody‐positive status at any post‐treatment time point were: cervical dystonia 4/312 (1.28%), glabellar lines 2/718 (0.28%), overactive bladder 0/22 (0%), post‐stroke spasticity 1/317 (0.32%), and primary axillary hyperhidrosis 4/871 (0.46%). Across all indications, 11/2,240 subjects (0.49%) converted from antibody negative at baseline to positive at one or more post‐treatment time points, but only three subjects became clinically unresponsive to onabotulinumtoxinA at some point following a positive assay. Based on these large trials, the frequency of antibody conversion after onabotulinumtoxinA treatment is very low, and infrequently leads to loss of efficacy. © 2010 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Canada</li>
<li>États-Unis</li>
</country>
<region><li>Bavière</li>
<li>Californie</li>
<li>District de Souabe</li>
<li>Massachusetts</li>
<li>Washington (État)</li>
</region>
<settlement><li>Augsbourg</li>
<li>Los Angeles</li>
</settlement>
</list>
<tree><country name="Allemagne"><region name="Bavière"><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name>
</region>
</country>
<country name="Canada"><noRegion><name sortKey="Carruthers, Alastair" sort="Carruthers, Alastair" uniqKey="Carruthers A" first="Alastair" last="Carruthers">Alastair Carruthers</name>
</noRegion>
<name sortKey="Carruthers, Jean" sort="Carruthers, Jean" uniqKey="Carruthers J" first="Jean" last="Carruthers">Jean Carruthers</name>
</country>
<country name="États-Unis"><region name="Washington (État)"><name sortKey="Aurora, Sheena K" sort="Aurora, Sheena K" uniqKey="Aurora S" first="Sheena K." last="Aurora">Sheena K. Aurora</name>
</region>
<name sortKey="Abu Hakra, Susan" sort="Abu Hakra, Susan" uniqKey="Abu Hakra S" first="Susan" last="Abu-Shakra">Susan Abu-Shakra</name>
<name sortKey="Abu Hakra, Susan" sort="Abu Hakra, Susan" uniqKey="Abu Hakra S" first="Susan" last="Abu-Shakra">Susan Abu-Shakra</name>
<name sortKey="Beddingfield, Frederick" sort="Beddingfield, Frederick" uniqKey="Beddingfield F" first="Frederick" last="Beddingfield">Frederick Beddingfield</name>
<name sortKey="Beddingfield, Frederick" sort="Beddingfield, Frederick" uniqKey="Beddingfield F" first="Frederick" last="Beddingfield">Frederick Beddingfield</name>
<name sortKey="Boodhoo, Terry" sort="Boodhoo, Terry" uniqKey="Boodhoo T" first="Terry" last="Boodhoo">Terry Boodhoo</name>
<name sortKey="Brin, Mitchell F" sort="Brin, Mitchell F" uniqKey="Brin M" first="Mitchell F." last="Brin">Mitchell F. Brin</name>
<name sortKey="Brin, Mitchell F" sort="Brin, Mitchell F" uniqKey="Brin M" first="Mitchell F." last="Brin">Mitchell F. Brin</name>
<name sortKey="Chapman, Mary Ann" sort="Chapman, Mary Ann" uniqKey="Chapman M" first="Mary Ann" last="Chapman">Mary Ann Chapman</name>
<name sortKey="Demos, George" sort="Demos, George" uniqKey="Demos G" first="George" last="Demos">George Demos</name>
<name sortKey="James, Lynn" sort="James, Lynn" uniqKey="James L" first="Lynn" last="James">Lynn James</name>
<name sortKey="Miller Essana, Mary Ann" sort="Miller Essana, Mary Ann" uniqKey="Miller Essana M" first="Mary Ann" last="Miller-Messana">Mary Ann Miller-Messana</name>
<name sortKey="Vandenburgh, Amanda" sort="Vandenburgh, Amanda" uniqKey="Vandenburgh A" first="Amanda" last="Vandenburgh">Amanda Vandenburgh</name>
<name sortKey="Zafonte, Ross" sort="Zafonte, Ross" uniqKey="Zafonte R" first="Ross" last="Zafonte">Ross Zafonte</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B85 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001B85 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:9D49D0608959680754775765CD828182E3869E3E
   |texte=   Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications

Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.